TECH · Bio-Techne Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.22B | $1.16B | $1.14B | $1.11B | $931.03M | $738.69M |
| Cost of Revenue | $429.36M | $389.33M | $366.89M | $349.10M | $298.18M | $255.50M |
| Gross Profit | $790.27M | $769.73M | $769.82M | $756.50M | $632.85M | $483.19M |
| R&D | $99.50M | $96.66M | $92.49M | $87.14M | $70.60M | $65.19M |
| SG&A | $588.52M | $466.38M | $378.38M | $372.77M | $324.95M | $260.58M |
| Total Operating Expenses | $688.02M | $563.04M | $470.87M | $459.91M | $395.55M | $325.77M |
| D&A | $109.90M | $111.71M | $107.24M | $101.07M | $87.75M | $82.74M |
| Operating Income | $102.25M | $206.69M | $298.94M | $296.59M | $237.30M | $157.42M |
| Interest Expense | $8.51M | $15.74M | $11.21M | $11.31M | $13.95M | $19.20M |
| Income Tax | $25.06M | $17.58M | $53.22M | $38.29M | $8.59M | $47.18M |
| Net Income | $73.40M | $168.10M | $285.26M | $272.05M | $140.41M | $229.30M |
| EPS - Basic | $0.47 | $1.07 | $1.81 | $1.73 | $0.91 | $1.50 |
| EPS - Diluted | $0.46 | $1.05 | $1.76 | $1.66 | $0.87 | $1.46 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $162.19M | $151.79M | $180.57M | $172.57M | $199.09M | $146.63M |
| Accounts Receivable | $206.88M | $241.39M | $218.47M | $194.55M | $145.38M | $122.53M |
| Inventory | $189.45M | $179.73M | $171.64M | $141.12M | $116.75M | $103.15M |
| Accounts Payable | $25.31M | $37.97M | $25.68M | $33.87M | $29.38M | $23.09M |
| Current Assets | $608.30M | $617.42M | $621.48M | $605.56M | $510.61M | $520.92M |
| Total Assets | $2.56B | $2.70B | $2.64B | $2.29B | $2.26B | $2.03B |
| Current Liabilities | $175.85M | $159.38M | $128.51M | $176.02M | $152.28M | $106.67M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | $1.92B | $2.07B | $1.97B | $1.70B | $1.56B | $1.38B |
| Retained Earnings | $1.07B | $1.33B | $1.31B | $1.12B | $1.09B | $1.06B |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $287.56M | $298.98M | $254.39M | $325.27M | $352.16M | $205.22M |
| Investing Cash Flow | ($35.18M) | ($203.03M) | ($265.65M) | ($96.85M) | ($243.52M) | $27.09M |
| Financing Cash Flow | ($253.91M) | ($122.40M) | $22.62M | ($242.85M) | ($62.55M) | ($183.80M) |
| CapEx | $31.01M | $62.88M | $38.24M | $44.91M | $44.30M | $51.74M |
| Free Cash Flow | $256.55M | $236.10M | $216.15M | $280.36M | $307.86M | $153.47M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 64.8% | 66.4% | 67.7% | 68.4% | 68.0% | 65.4% |
| Operating margin | 8.4% | 17.8% | 26.3% | 26.8% | 25.5% | 21.3% |
| EBITDA margin | 17.4% | 27.5% | 35.7% | 36.0% | 34.9% | 32.5% |
| Net margin | 6.0% | 14.5% | 25.1% | 24.6% | 15.1% | 31.0% |
| Free cash flow margin | 21.0% | 20.4% | 19.0% | 25.4% | 33.1% | 20.8% |
| FCF / Net income | 3.50 | 1.40 | 0.76 | 1.03 | 2.19 | 0.67 |
| R&D / Revenue | 8.2% | 8.3% | 8.1% | 7.9% | 7.6% | 8.8% |
| SG&A / Revenue | 48.3% | 40.2% | 33.3% | 33.7% | 34.9% | 35.3% |
| Effective tax rate | 25.5% | 9.5% | 15.7% | 12.3% | 5.8% | 17.1% |
| Return on assets | 2.9% | 6.2% | 10.8% | 11.9% | 6.2% | 11.3% |
| Return on equity | 3.8% | 8.1% | 14.5% | 16.0% | 9.0% | 16.6% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 3.46 | 3.87 | 4.84 | 3.44 | 3.35 | 4.88 |
| Quick ratio | 2.38 | 2.75 | 3.50 | 2.64 | 2.59 | 3.92 |
| Cash ratio | 0.92 | 0.95 | 1.41 | 0.98 | 1.31 | 1.37 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | 12.0x | 13.1x | 26.7x | 26.2x | 17.0x | 8.2x |
| Equity multiplier | 1.33 | 1.31 | 1.34 | 1.35 | 1.45 | 1.47 |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | 0.48 | 0.43 | 0.43 | 0.48 | 0.41 | 0.36 |
| Inventory turnover | 2.27 | 2.17 | 2.14 | 2.47 | 2.55 | 2.48 |
| Days sales outstanding | 62d | 76d | 70d | 64d | 57d | 61d |
| Days inventory outstanding | 161d | 168d | 171d | 148d | 143d | 147d |
| Days payable outstanding | 22d | 36d | 26d | 35d | 36d | 33d |
| Cash conversion cycle | 201d | 209d | 215d | 176d | 164d | 175d |
| Valuation | ||||||
| P / E | 120.9x | 68.2x | 46.4x | 52.3x | 129.8x | 45.4x |
| P / B | 4.6x | 5.6x | 6.7x | 2.1x | 2.9x | 1.9x |
| P / S | 7.3x | 9.9x | 11.6x | 3.2x | 4.9x | 3.5x |
| EV / EBITDA | 41.1x | 35.7x | 32.1x | 8.5x | 13.4x | 10.2x |
| Growth | ||||||
| Revenue growth (YoY) | 5.2% | 2.0% | 2.8% | 18.7% | 26.0% | 31.2% |
| Revenue CAGR (3y) | 3.3% | 7.6% | 15.5% | 25.2% | - | 9.5% |
| Revenue CAGR (5y) | 10.5% | 15.5% | - | 14.5% | 13.3% | 10.3% |
| Gross profit growth (YoY) | 2.7% | -0.0% | 1.8% | 19.5% | 31.0% | 2.0% |
| Operating income growth (YoY) | -50.5% | -30.9% | 0.8% | 25.0% | 50.7% | 7.3% |
| Net income growth (YoY) | -56.3% | -41.1% | 4.9% | 93.8% | -38.8% | 138.7% |
| EPS growth (YoY) | -56.2% | -40.3% | 6.2% | 91.1% | -40.4% | -41.1% |
| EPS CAGR (3y) | -34.8% | 6.6% | 6.5% | -12.5% | -36.0% | -10.5% |
| EPS CAGR (5y) | -20.6% | -15.7% | -11.9% | -4.0% | -20.9% | -12.8% |
| FCF growth (YoY) | 8.7% | 9.2% | -22.9% | -8.9% | 100.6% | -1.8% |
| FCF CAGR (5y) | 10.8% | 8.6% | 11.9% | 16.9% | 19.4% | 5.1% |
| Book value growth (YoY) | -7.3% | 5.2% | 15.6% | 8.9% | 13.2% | 18.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-06-30.
Business segments
$1.22B totalProtein Sciences$870.25M · 71.5%
Diagnostics And Spatial Biology$346.26M · 28.5%
Product / service
$2.42B totalProduct And Services$1.20B · 49.5%
Consumables$972.29M · 40.3%
Instruments$112.09M · 4.6%
Service$111.57M · 4.6%
Royalty$23.69M · 1.0%
Geographic
$1.22B totalUS$683.23M · 56.0%
EMEAExcluding UK$266.31M · 21.8%
CN$100.46M · 8.2%
APACExcluding Greater China$77.26M · 6.3%
GB$54.83M · 4.5%
Rest Of World$37.55M · 3.1%
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing BIO-TECHNE Corp against the 5 most active filers in the same SIC group.
Dividends
$0.32/share trailing 12 months · 0.0% YoY
| Ex-date | Per share |
|---|---|
| May 18, 2026 | $0.0800 |
| Feb 13, 2026 | $0.0800 |
| Nov 17, 2025 | $0.0800 |
| Aug 18, 2025 | $0.0800 |
| May 19, 2025 | $0.0800 |
| Feb 14, 2025 | $0.0800 |
| Nov 8, 2024 | $0.0800 |
| Aug 19, 2024 | $0.0800 |
| May 10, 2024 | $0.0800 |
| Feb 9, 2024 | $0.0800 |
| Nov 9, 2023 | $0.0800 |
| Aug 17, 2023 | $0.0800 |
| May 12, 2023 | $0.0800 |
| Feb 10, 2023 | $0.0800 |
| Nov 10, 2022 | $0.0800 |
| Aug 12, 2022 | $0.0800 |
| May 13, 2022 | $0.0800 |
| Feb 10, 2022 | $0.0800 |
| Nov 10, 2021 | $0.0800 |
| Aug 13, 2021 | $0.0800 |
| May 14, 2021 | $0.0800 |
| Feb 11, 2021 | $0.0800 |
| Nov 13, 2020 | $0.0800 |
| Aug 17, 2020 | $0.0800 |